Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression‐free survival based on reconstructed individual patient data

Published:2022-08-03 Issue:3 Volume:12 Page:2155-2165
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Ossato Andrea¹,Damuzzo Vera¹^ORCID,Baldo Paolo²^ORCID,Mengato Daniele³^ORCID,Chiumente Marco³^ORCID,Messori Andrea⁴^ORCID

Affiliation:

1. Department of Pharmaceutical and Pharmacological Sciences University of Padova Padova Italy

2. Centro di Riferimento Oncologico di Aviano IRCCS Aviano Italy

3. Italian Society of Clinical Pharmacy and Therapeutics‐SIFaCT Milan Italy

4. HTA Unit, Regione Toscana, Regional Health Service Florence Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5067

Reference23 articles.

1. The future of immune checkpoint therapy

2. Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies

3. Immune checkpoint inhibitors in melanoma

4. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance

5. Melanoma: An Update on Systemic Therapies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data;Frontiers in Oncology;2024-07-04

2. Relatlimab–nivolumab: A practical overview for dermatologists;Journal of the American Academy of Dermatology;2023-11

3. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma;Journal of Managed Care & Specialty Pharmacy;2023-11

4. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses;Cancers;2023-03-07

5. Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody;Cureus;2022-12-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3